207 related articles for article (PubMed ID: 27600285)
21. Effect of intensive lipid-lowering treatment compared to moderate lipid-lowering treatment with rosuvastatin on endothelial function in high risk patients.
Egede R; Jensen LO; Hansen HS; Antonsen L; Hansen KN; Junker A; Thayssen P
Int J Cardiol; 2012 Jul; 158(3):376-9. PubMed ID: 21349594
[TBL] [Abstract][Full Text] [Related]
22. Association of the LIPG 584C > T polymorphism and serum lipid levels in the Guangxi Bai Ku Yao and Han populations.
Liu WY; Yin RX; Zhang L; Cao XL; Miao L; Wu DF; Aung LH; Hu XJ; Lin WX; Yang DZ
Lipids Health Dis; 2010 Oct; 9():110. PubMed ID: 20923576
[TBL] [Abstract][Full Text] [Related]
23. High-dose statin therapy with rosuvastatin reduces small dense LDL and MDA-LDL: The Standard versus high-dose therApy with Rosuvastatin for lipiD lowering (SARD) trial.
Nishikido T; Oyama J; Keida T; Ohira H; Node K
J Cardiol; 2016 Apr; 67(4):340-6. PubMed ID: 26162946
[TBL] [Abstract][Full Text] [Related]
24. Lipoprotein lipase HindIII polymorphism influences HDL-cholesterol levels in statin-treated patients with coronary artery disease.
Javorský M; Gasperíková D; Ukropec J; Sedláková B; Riecanský I; Krizanová O; Seböková E; Dobríková M; Klimes I; Tkác I
Wien Klin Wochenschr; 2007; 119(15-16):476-82. PubMed ID: 17721767
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of the intensive dose of rosuvastatin 40mg/day in patients with acute coronary syndrome and at high risk of cardiovascular disease-ROSUVEES-2.
Shah CP; Shah BP; Dani SI; Channa BB; Lakshmanan SS; Krishnamani NC; Mehta A; Moorthy P
Indian Heart J; 2016; 68(6):766-771. PubMed ID: 27931543
[TBL] [Abstract][Full Text] [Related]
26. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial.
Ballantyne CM; Raichlen JS; Cain VA
J Am Coll Cardiol; 2008 Aug; 52(8):626-32. PubMed ID: 18702965
[TBL] [Abstract][Full Text] [Related]
27. LEGACY: Phase 2a Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of the Anti-EL (Endothelial Lipase) Antibody MEDI5884 in Patients With Stable Coronary Artery Disease.
Ruff CT; Koren MJ; Grimsby J; Rosenbaum AI; Tu X; Karathanasis SK; Falloon J; Hsia J; Guan Y; Conway J; Tsai LF; Hummer BT; Hirshberg B; Kuder JF; Murphy SA; George RT; Sabatine MS
Arterioscler Thromb Vasc Biol; 2021 Dec; 41(12):3005-3014. PubMed ID: 34706556
[TBL] [Abstract][Full Text] [Related]
28. Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy.
Poduri A; Khullar M; Bahl A; Sehrawat BS; Sharma Y; Talwar KK
DNA Cell Biol; 2010 Oct; 29(10):629-37. PubMed ID: 20578904
[TBL] [Abstract][Full Text] [Related]
29. Association of endothelial lipase gene-384A/C with coronary artery disease in Han Chinese people.
Xie L; Sun Y; Tong Y; Liu Y; Deng Y
BMJ Open; 2015 Jun; 5(6):e007621. PubMed ID: 26124511
[TBL] [Abstract][Full Text] [Related]
30. [Relationship between polymorphisms of interleukin 10 promoter and serum levels of lipoprotein in the Chinese Han population].
Du R; Pan SY; Lu BX; Zeng FY
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Apr; 24(2):206-9. PubMed ID: 17407084
[TBL] [Abstract][Full Text] [Related]
31. Hepatic lipase gene -514 C/T polymorphism and premature coronary heart disease.
Ji J; Herbison CE; Mamotte CD; Burke V; Taylor RR; van Bockxmeer FM
J Cardiovasc Risk; 2002 Apr; 9(2):105-13. PubMed ID: 12006918
[TBL] [Abstract][Full Text] [Related]
32. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A;
Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888
[TBL] [Abstract][Full Text] [Related]
33. [Influence of CETP gene -629C/A polymorphism on the efficacy of atorvastatin treatment and clinical outcome].
Gao J; Cong HL; Mao YM; Liu Y; Zhang N; Chen Q; Liu T; Cui R
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Oct; 30(5):553-8. PubMed ID: 24078569
[TBL] [Abstract][Full Text] [Related]
34. Effect of intensive lipid-lowering therapies on cholinesterase activity in patients with coronary artery disease.
Pytel E; Bukowska B; Koter-Michalak M; Olszewska-Banaszczyk M; Gorzelak-Pabiś P; Broncel M
Pharmacol Rep; 2017 Feb; 69(1):150-155. PubMed ID: 27923158
[TBL] [Abstract][Full Text] [Related]
35. Common variants in the genes of triglyceride and HDL-C metabolism lack association with coronary artery disease in the Pakistani subjects.
Shahid SU; Shabana NA; Cooper JA; Rehman A; Humphries SE
Lipids Health Dis; 2017 Jan; 16(1):24. PubMed ID: 28143480
[TBL] [Abstract][Full Text] [Related]
36. Lipid-Associated GWAS Loci Predict Antiatherogenic Effects of Rosuvastatin in Patients with Coronary Artery Disease.
Kononov S; Azarova I; Klyosova E; Bykanova M; Churnosov M; Solodilova M; Polonikov A
Genes (Basel); 2023 Jun; 14(6):. PubMed ID: 37372439
[TBL] [Abstract][Full Text] [Related]
37. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.
Jukema JW; Liem AH; Dunselman PH; van der Sloot JA; Lok DJ; Zwinderman AH
Curr Med Res Opin; 2005 Nov; 21(11):1865-74. PubMed ID: 16307708
[TBL] [Abstract][Full Text] [Related]
38. [The -384A >C polymorphism of endothelial lipase gene promoter region in Chinese healthy normolipidemic and endogenous hypertriglyceridemic subjects].
Huang Y; Bai H; Fan P; Liu R; Liu Y; Liu BW
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Aug; 25(4):443-6. PubMed ID: 18683147
[TBL] [Abstract][Full Text] [Related]
39. Apolipoprotein-E polymorphism and response to pravastatin in men with coronary artery disease (REGRESS).
Maitland-van der Zee AH; Jukema JW; Zwinderman AH; Hallman DM; De Boer A; Kastelein JJ; De Knijff P
Acta Cardiol; 2006 Jun; 61(3):327-31. PubMed ID: 16869455
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of alirocumab for reducing plaque vulnerability: Study protocol for ALTAIR, a randomized controlled trial in Japanese patients with coronary artery disease receiving rosuvastatin.
Otake H; Sugizaki Y; Toba T; Nagano Y; Tsukiyama Y; Yanaka KI; Yamamoto H; Nagasawa A; Onishi H; Takeshige R; Nakano S; Matsuoka Y; Tanimura K; Kawamori H; Shinke T; Hirata KI
J Cardiol; 2019 Mar; 73(3):228-232. PubMed ID: 30579806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
